anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a means for improving or preventing alopecia and sparse hair, particularly stress-related alopecia and sparse hair.  <P>SOLUTION: The hair growing material composed of extracts of the following crude medicines or the following components is added to an external preparation for skin, preferably a hair cosmetic. These crude medicines include Rosa roxburghii of the family Rosaceae, Foeniculum vulgare Mill. of the family Umbelliferae, Malva sylvestris L. of the family Malvaceae, Rose Fruit of the family Rosaceae, apricot of the family Rosaceae, whitethorn of the family Rosaceae, Citrus unshu Marc. of the family Rutaceae, Ophipogonis Tube of the family Liliaceae, loquat of the family Rosaceae, Ruscus aculeatus L. of the family Liliaceae, Artemisia princeps of the family Compositae, Sanguisorba officinalis L. of the family Rosaceae, Ononis spinosa L. of the family Leguminosae, seaweed, Simmondssia Chinensis, Citrus reticulata Blanco of the family Rutaceae, Salvia officinalis L. of the family Labiatae, Humulus lupulus L. of the family Moraceae, Plectranthus rugosus of the family Labiatae, Ligusticum wallichii Franch. of the family Umbelliferae. Rosa of the family Rosaceae, Ginkgo biloba L. of the family Ginkgoaceae, Eugenia aromatica of the family Myrtaceae or the like. These components include vitamin E nicotinate, an extract of pearl protein or the like.  <P>COPYRIGHT: (C)2004,JPO
BACKGROUND: The potential influence of tinnitus on cardiovascular disease (CVD) and all-cause mortality has yet to be explored. We aim to examine the correlations between tinnitus and the risk of cardiovascular events and all-cause mortality.
METHODS: We conducted a prospective cohort study utilising data from the UK Biobank. The presence of tinnitus was evaluated through a questionnaire. The primary outcome was defined as a composition of cardiovascular events, including myocardial infarction (MI), stroke, and mortality from CVD, as well as all-cause mortality. Cox proportional hazard models were employed to examine the associations between tinnitus and both the primary outcome and its individual components. Sensitivity analyses were conducted to evaluate the robustness of the primary analysis.
RESULTS: A total of 140,146 participants were included in the study. The presence of tinnitus was found to be associated with a higher incident rate of the primary outcome (HR = 1.057, 95%CI: 1.017-1.099, p = 0.005), MI (HR = 1.139, 95%CI: 1.061-1.222, p < 0.001) and all-cause mortality (HR = 1.053, 95%CI: 1.003-1.105, p = 0.038) after adjusting for confounders. However, there was no significant association between tinnitus and stroke or mortality from CVD. Subgroup analysis revealed that the association between tinnitus and the primary outcome was significant in females, participants with abnormal BMI, and those without hearing difficulty, depression or anxiety. Sensitivity analyses yielded consistent results.
CONCLUSION: The findings from this study contribute to the existing body of evidence suggesting an association between tinnitus and an increased risk of cardiovascular events and all-cause mortality.
The present invention provides an antibody or antigen-binding fragment thereof capable of specifically recognizing IL-11. The antibody comprises heavy chain variable region CDRs shown as SEQ ID NO. 4-6, light chain variable region CDRs shown as SEQ ID NO. 37-39, heavy chain framework regions shown as SEQ ID NO. 67-70, and light chain framework regions shown as SEQ ID NO. 71-74. The antibody has low immunogenicity, can specifically target and bind IL-11, and blocks the binding of IL-11 and IL-11 receptor.
Salsalate is a non-steroid anti-inflammatory drug. Subjects taking 2 or 4g of fish oil capsules will be randomized to take in addition 1.5 or 3.0 g of salsalate per day. The combined treatment of fish oil and salsalate will continue for 8 weeks.
Patients received 4 sessions, separated one week between them. The treatment consisted the application of a galvanic current through an acupuncture needle (0,30x30mm). The approach were performed with a transverse axis with a needle in plane, being superficial and deep interface of medium nerve the target tissue. The parameters will be 2 mA (milliamps), 10 seconds, 3 impacts (3: 3: 3).
OBJECTIVE: Both microRNA (miR)-105-5p and SPARCL1 were discovered to be differentially expressed in osteoarthritis (OA), but their roles and exact mechanisms have not been entirely elaborated. This paper sets out to probe the impact of miR-105-5p/SPARCL1 on chondrocyte injury, extracellular matrix degradation, and osteoarthritis progression.
METHODS: C28/I2 cells were stimulated with IL-1β to construct an in vitro OA model. C28/I2 cells were transfected with sh-SPARCL1, oe-SPARCL1, or miR-105-5p mimic before IL-1β induction. CCK-8 assay, flow cytometry, and ELISA were adopted to assess cell viability, apoptosis, and inflammatory factor expression, respectively. The binding relationship of miR-105-5p to SPARCL1 was assessed using dual-luciferase reporter assay. After an OA rat model was established, rats underwent intra-articular injection with ago-miR-105-5p. TUNEL was applied to determine cell apoptosis in vivo. mRNA and protein levels were measured by qRT-PCR and western blot, respectively, in vitro and in vivo.
RESULTS: IL-1β treatment diminished miR-105-5p expression and augmented SPARCL1 expression in C28/I2 cells. miR-105-5p decreased SPARCL1 expression by targeting SPARCL1. miR-105-5p overexpression or SPARCL1 silencing prominently reversed the decrease in viability and the promotion of inflammatory factor production, cartilage matrix degradation, and apoptosis in IL-1β-stimulated C28/I2 cells. Furthermore, upregulation of SPARCL1 nullified the influence of miR-105-5p overexpression on viability, apoptosis, inflammation, and cartilage matrix degradation in IL-1β-stimulated C28/I2 cells. miR-105-5p overexpression ameliorated knee cartilage tissue injury in OA rats.
CONCLUSION: Conclusively, miR-105-5p exerted suppressive effects on chondrocyte injury, extracellular matrix degradation, and OA progression by targeting SPARCL1.
A method for generative evidence of a diversion event is provided. The method includes detecting a triggering event at a dispensing cabinet including medication. The method also includes activating, in response to the detection of the triggering event, one or more surveillance devices to capture a recording. The recording includes a possible diversion event. The method also includes generating one or more transaction records associated with the recording. The method also includes filtering, at a database and based on one or more of the transaction records, a plurality of recordings. The plurality of recordings includes the recording to determine whether the possible diversion event occurred. In response to a determination that the possible diversion event occurred, the method includes generating an alert indicating that the possible diversion event has occurred. Related systems and articles of manufacture, including apparatuses and computer program products, are also disclosed.
In the present invention there are disclosed compounds of the general formula I, in which X and X? form together with a carbon atom to which they are attached the group C=O or C=NOR wherein R represents a hydrogen atom a heterocyclic group containing at least one nitrogen atom or a straight or branched or cyclic alkyl, alkenyl or alkynyl group and the other general symbols have specific meanings. Preparation process of the above compounds comprises reacting acid in aqueous medium with the starting substance, blocking the hydroxyl group in position 2?, oxidation of the hydroxyl group in position 3, introducing the Ri3? group, having the same meaning as Ri3 except for a hydrogen atom, deblocking the 2? hydroxyl group, treating the reaction mixture with an oximation agent and esterification thereof to obtain salts of the compounds of the general formula I. The invented derivatives are usable for treating infections caused by infectious germs responsive to antibiotics.
PURPOSE:To separate and purify the titled substance from a plasma protein mixture liquid, by extracting the specific bonding site of antithrombin III from natural sulfated hydrocarbon, bonding the extract to a hydrophilic carrier, and contacting the resultant gel with the plasma protein mixture. CONSTITUTION:Heparin which is a natural sulfated mucopolysaccharide, or its acetylated derivative, is decomposed by digesting with a specific enzyme such as heparinase, etc. or by deamination decomposition. The obtained oligosaccharide is purified by affinity chromatography, etc. using antithrombin III sepharose, lysine sepharose, etc. to obtain a fragment bonded with antithrombin III. The ligand is immobilized to a hydrophilic carrier by a firm bonding method, and the obtained gel is brought into contact with a plasma protein mixture liquid to effect the specific adsorption of the antithrombin III from the mixture. The adsorbed antithrombin III is desorbed to obtain purified antithrombin III. EFFECT:The purification can be carried out rapidly and easily in high efficiency, and the ingredient proteins can be effectively removed by this process.
This is a method of treating a wide range of skin lesions in tropical and decorative fish in which the animals to be treated are exposed to dilute suspensions of colloidal silver. During the course of treatment, colloidal silver is added periodically to the aquarium in which the fish lives. so that the water therein has a silver concentration on the order of 1 ppb. A suitable treatment procedure entails adding 1 teaspoon of colloidal silver which contains about 6 ppm of silver to 10 gallons of aquarium water every other day. This treatment has been found effective in healing some fish, ever those with rather large wounds in a matter of days. If a longer treatment period is required, then the colloidal silver addition is continued at the same rate and then 50 percent of the water is changed once a week, until the lesion(s) have healed. It was also found that bacteria and virus skin problems could be prevented by having silver colloidal concentrations of 0.3-0.5 ppb in the aquarium water.
INTRODUCTION: High-grade cervical intraepithelial neoplasia (CIN), a premalignant lesion of the uterine cervix, is caused by persistent Human Papillomavirus (HPV) infection. CIN can be identified through screening programs and high-grade CIN is usually treated by ablation or excision. This study aimed to summarize the clinical management and outcomes among women with high-grade CIN in Europe.
METHODS: A systematic literature review was conducted to identify treatment methods and their frequency of use, report HPV genotype prevalence and distribution and summarize patterns for subsequent lesions after primary treatment, among women with high-grade CIN in Europe. Embase®, MEDLINE® and Cochrane databases were searched (1st January 2012 to 30th August 2022), along with relevant conference proceedings (2018-2022), inclusive. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) compliant methodology was adopted. Eligibility criteria included non-immunosuppressed female patients with CIN2+ from Europe (published in English).
RESULTS: In total, n = 55 studies were included. CIN excisional therapy was the most received treatment approach (15.8-100 %, loop electrosurgical excision procedure/large loop excision of the transformation zone most common), followed by ablative therapies (1-43.3 %, cold coagulation most common). Other approaches included 'wait and watch' (4.8-52.6 %) and hysterectomy (4.8-16.2 %). HPV positivity rates ranged from 67.8-100 % pre-conization and 4.7-32.8 % post-conization. The most prevalent HPV genotypes reported (both pre- and post-treatment) were HPV16 and HPV18. In patients who received excisional or ablative procedures subsequent CIN was most frequently diagnosed ≤6 months after treatment. The overall rate of subsequent CIN reported was 0.5-20.9 %.
CONCLUSION: Conization and ablation were the most common techniques, however, these procedures were associated with sub-optimal outcomes. Close clinical follow-up is important due to the risk of subsequent CIN or invasive cancer. This review serves as a reference point for the comparison of future treatment patterns as they evolve across Europe, following improved implementation of prophylactic HPV vaccination and screening.
Developing genetically resistant soybean cultivars is key in controlling the destructive Sclerotinia Stem Rot (SSR) disease. Here, a GWAS study in Canadian soybeans identified potential marker-trait associations and candidate genes, paving the way for more efficient breeding methods for SSR. Sclerotinia stem rot (SSR), caused by the fungal pathogen Sclerotinia sclerotiorum, is one of the most important diseases leading to significant soybean yield losses in Canada and worldwide. Developing soybean cultivars that are genetically resistant to the disease is the most inexpensive and reliable method to control the disease. However, breeding for resistance is hampered by the highly complex nature of genetic resistance to SSR in soybean. This study sought to understand the genetic basis underlying SSR resistance particularly in soybean grown in Canada. Consequently, a panel of 193 genotypes was assembled based on maturity group and genetic diversity as representative of Canadian soybean cultivars. Plants were inoculated and screened for SSR resistance in controlled environments, where variation for SSR phenotypic response was observed. The panel was also genotyped via genotyping-by-sequencing and the resulting genotypic data were imputed using BEAGLE v5 leading to a catalogue of 417 K SNPs. Through genome-wide association analyses (GWAS) using FarmCPU method with threshold of FDR-adjusted p-values < 0.1, we identified significant SNPs on chromosomes 2 and 9 with allele effects of 16.1 and 14.3, respectively. Further analysis identified three potential candidate genes linked to SSR disease resistance within a 100 Kb window surrounding each of the peak SNPs. Our results will be important in developing molecular markers that can speed up the breeding for SSR resistance in Canadian grown soybean.
The study population were children aged 2-12 years (weight 12-40 kg) suffering from upper respiratory tract infections (acute otitis media, tonsillitis, pharyngitis, or acute bacterial bronchitis) and who needed antibiotic treatment. The study compared treatment satisfaction and treatment adherence of oral clarithromycin DST (125 mg, 187.5 mg, or 250 mg twice daily) with the established oral clarithromycin syrup administered via a graduated syringe (Klacid Syrup Forte®, 250 mg/5mL) at the same fixed daily doses.

Fixed doses of 125 mg, 187.5 mg and 250 mg of clarithromycin DST offer the pediatrician the flexibility to treat children of different body weight and age adequately at the recommended daily dose of 15 (12.5-20) mg/kg. All children were treated for 7 to 10 day (14 to 20 doses). Treatment satisfaction by the guardian/caregiver in terms of handling and administration of the clarithromycin DST straw and the comparator clarithromycin syrup, convenience of the administration, acceptance of taste and aftertaste, and treatment satisfaction with respect to future use was evaluated by means of a Parents' Questionnaire once on either Day 3, 4, or 5 and once on either Day 11, 12, 13, or 14. In addition, treatment adherence/willingness of medication intake and the child's health status were assessed. The safety program comprised recording and evaluation of adverse events and countermeasures.
The invention relates to an ofloxacin molecular inclusion nanometer preparation and a preparation method thereof, belonging to the technical field of medicines. The main raw materials of the molecular inclusion nanometer preparation are cyclodextrin, solubilizer, polymer materials, ofloxacin and the like. The preparation method comprises the steps of: adding the cyclodextrin after dissolving the ofloxacin in a solution containing the solubilizer and preparing a molecular inclusion compound through a gradient ultrasonic grinding method; then adding the polymer materials for grinding; and drying and smashing to obtain the ofloxacin molecular inclusion nanometer preparation. The average particle size of the molecular inclusion nanometer preparation is 252.3 nm; and the drug content is 1%-25%. The preparation method, disclosed by the invention, has the advantages of being simple in a preparation process, high in drug carrying amount and stability, controllable in quality, suitable for industrial production and the like. The ofloxacin molecular inclusion nanometer preparation prepared by the method has the advantages of efficiently improving stability of the drug and dissolution degree as well as dissolution speed of the drug in a gastrointestinal tract, improving a drug absorption rate, realizing rapid and efficient effects, masking bitter taste of the drug, reducing drug irradiation and improving drug palatability and drug availability.
A solid, uniform and stable preparation for the treatment of affections of the central nervous system is prepared by mixing assimilable forms of the alkaloids hyoscyamine, atropine and scopalamine in such preportions that the hyoscyamine is 75.5 to 95 per cent, the atropine 20.0 to 1.5 per cent and the scopalamine 5 to 0.5 per cent by weight of the total alkaloid content of the preparation.  Assimilable forms are the alkaloid salts with mineral acids such as hydrobromide, hydrochloride and sulphate or with organic acids, such as tartrate, acetate and lactate, so long as such salts are soluble in aqueous or alcoholic solution. The alkaloids may also be used per se.  A preferred composition comprises hyoscyamine hydrobromide, atropine sulphate and scopalamine hydrobromide.  Other therapeutic materials such as citric acid and ammonium chloride may be present.  An example is given of a tablet containing the alkaloids, milk sugar, sucrose, starch, acacia, talc and medicinal paraffin.
Metformin is an anti-diabetic drug that is known improve insulin sensitivity and reduce insulin resistance. A published meta-analysis of randomized controlled trials (RCTs) reported a reduction of weight and insulin resistance in metformin users. Animal models also showed that metformin reduces cardiac hypertrophy. Observational studies showed a beneficial effect for metformin in patients with type 2 diabetes mellitus (T2DM) and heart failure. A recent study found that metformin reduced oxidative stress in non-diabetic patients with CAD.

Metformin has multiple modes of actions involving both AMP-activated protein kinase (AMPK) dependent and AMPK-independent mechanisms that may be implicated in cardiac hypertrophy. At the systemic level, a review of clinical and experimental data showed that metformin improves endothelial function, protects from oxidative stress and inflammation, as well as the negative effects of angiotensin II. Observational studies also reported cardiovascular benefits in metformin users especially in patients with type 2 diabetes mellitus (T2DM) and heart failure. Metformin has also been shown to exert a cardio protective effect and it has been shown to reduce oxidative stress which is a common finding in heart failure patients. For these reasons, there is an increasing interest in the use of metformin in CV diseases and there is an increasing interest in studying its potential new roles in this aspect. We hypothesized that metformin might improve morbidity, mortality, cardiac function, and HR-QoL in non-diabetic patients with HFrEF.
Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
Liver fibrosis is the consequence of chronic liver injury in the presence of an inflammatory component. Although the main executors of this activation are known, the mechanisms that lead to the inflammatory process that mediates the production of pro-fibrotic factors are not well characterized. Epidermal growth factor receptor (EGFR) signaling in hepatocytes is essential for the regenerative processes of the liver; however, its potential role in regulating the fibrotic niche is not yet clear. Our group generated a mouse model that expresses an inactive truncated form of the EGFR specifically in hepatocytes (ΔEGFR mice). Here, we have analyzed the response of WT and ΔEGFR mice to chronic treatment with carbon tetrachloride (CCl4), which induces a pro-inflammatory and fibrotic process in the liver. The results indicated that the hallmarks of liver fibrosis were attenuated in CCl4-treated ΔEGFR mice when compared with CCl4-treated WT mice, coinciding with a faster resolution of the fibrotic process and ameliorated damage. The absence of EGFR activity in hepatocytes induced changes in the pattern of immune cells in the liver, with a notable increase in the population of M2 macrophages, more related to fibrosis resolution, as well as in the population of lymphocytes related to eradication of the damage. Transcriptome analysis of hepatocytes, and secretome studies of extracellular media from in vitro experiments, allowed us to elucidate the specific molecular mechanisms regulated by EGFR that mediate hepatocyte production of both pro-fibrotic and pro-inflammatory mediators; these have consequences for the deposition of extracellular matrix proteins, as well as for the immune microenvironment. Overall, our study uncovered novel mechanistic insights regarding EGFR kinase-dependent actions in hepatocytes that reveal its key role in chronic liver damage. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.